Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 13/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18238032 | 0.75 | HTT (0.33) | LMNA | |
| SCHEMBL20731177 | 0.71 | LRRK2 (0.36) | LRRK2 | |
| SCHEMBL23938104 | 0.71 | LRRK2 (0.36) | LRRK2 | |
| SCHEMBL21685792 | 0.68 | LMNA (0.38) | LRRK2MEN1ABCC4LMNAPKM | |
| SCHEMBL21087557 | 0.67 | LRRK2 (0.53) | LRRK2 | |
| SCHEMBL23938018 | 0.66 | HTR2A (0.33) | MEN1KMT2A | |
| SCHEMBL23937696 | 0.66 | CYP19A1 (0.38) | LRRK2DYRK1A | |
| SCHEMBL30557564 | 0.64 | ADORA2A (0.39) | MEN1KMT2A | |
| SCHEMBL21685893 | 0.64 | NOTUM (0.41) | LRRK2MEN1KMT2A | |
| SCHEMBL27255854 | 0.61 | KDM4E (0.45) | MEN1LMNAPKMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO EARLY DISCOVERY, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | LRRK2 3122/4885DYRK1A 2644/4885MEN1 3554/4885 |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | USP28, USP25, USP24 | LRRK2 3122/4885DYRK1A 2644/4885MEN1 3554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.